Atopic Dermatitis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Atopic Dermatitis - Pipeline Review, H2 2016

Atopic Dermatitis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Atopic Dermatitis - Pipeline Review, H2 2016
Published Aug 10, 2016
375 pages — Published Aug 10, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Atopic Dermatitis - Pipeline Review, H2 2016, provides an overview of the Atopic Dermatitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atopic Dermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atopic Dermatitis and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Atopic Dermatitis
- The report reviews pipeline therapeutics for Atopic Dermatitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Atopic Dermatitis therapeutics and enlists all their major and minor projects
- The report assesses Atopic Dermatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Atopic Dermatitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Atopic Dermatitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Atopic Dermatitis pipeline depth and focus of Indication th

  
Source:
Document ID
GMDHC8341IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents219
  List of Tables173
  List of Figures201
Introduction211
  Global Markets Direct Report Coverage211
Atopic Dermatitis Overview221
Therapeutics Development232
  Pipeline Products for Atopic Dermatitis Overview231
  Pipeline Products for Atopic Dermatitis Comparative Analysis241
Atopic Dermatitis Therapeutics under Development by Companies256
Atopic Dermatitis Therapeutics under Investigation by Universities/Institutes311
Atopic Dermatitis Pipeline Products Glance324
  Late Stage Products321
  Clinical Stage Products331
  Early Stage Products341
  Unknown Stage Products351
Atopic Dermatitis Products under Development by Companies368
Atopic Dermatitis Products under Investigation by Universities/Institutes441
Atopic Dermatitis Companies Involved in Therapeutics Development4577
  AbbVie Inc451
  Accolade Pharmaceuticals, LLC461
  AlbireoPharma471
  Almirall, S.A.481
  Amgen Inc.491
  Amorepacific Corporation501
  Anacor Pharmaceuticals, Inc.511
  AnaMar AB521
  AnaptysBio, Inc.531
  AnGes MG, Inc.541
  arGEN-X BV551
  Avexxin AS561
  Blueberry Therapeutics Ltd571
  Brickell Biotech, Inc.581
  Celgene Corporation591
  Cell Medica Limited601
  Cellceutix Corporation611
  ChemoCentryx, Inc.621
  ChironWells GmbH631
  Chugai Pharmaceutical Co., Ltd.641
  Creabilis SA651
  Curapel Limited661
  Dermala Inc671
  Dr. August Wolff GmbH &Co. KG Arzneimittle681
  Eli Lilly and Company691
  F. Hoffmann-La Roche Ltd.701
  Foamix Pharmaceuticals Ltd.711
  Fountain Biopharma Inc.721
  Galapagos NV731
  GlaxoSmithKline Plc741
  Glenmark Pharmaceuticals Ltd.751
  Grupo Ferrer Internacional, S.A.761
  Han Wha Pharma Co., Ltd.771
  HanAll Biopharma Co., Ltd.781
  Heptares Therapeutics Limited791
  Herantis Pharma Plc801
  iCo Therapeutics Inc.811
  Immune Pharmaceuticals Inc.821
  Inflamalps SA831
  Japan Tobacco Inc.841
  Johnson &Johnson851
  Kang Stem Biotech Co., Ltd.861
  KPI Therapeutics, Inc.871
  LegoChem Biosciences, Inc881
  LEO Pharma A/S891
  Madam Therapeutics B.V.901
  MedImmune, LLC911
  NeoPharm Co., Ltd.921
  Nippon Shinyaku Co., Ltd.931
  Novan, Inc.941
  Novartis AG951
  Orbis Biosciences Inc961
  Otsuka Holdings Co., Ltd.971
  Oxagen Limited981
  Pfizer Inc.991
  Pharis Biotec GmbH1001
  Pharmedartis GmbH1011
  Provectus Biopharmaceuticals, Inc.1021
  PuriCore Plc1031
  Quorum Innovations LLC1041
  Regeneron Pharmaceuticals Inc1051
  Signum Dermalogix, Inc1061
  Spherium Biomed S.L.1071
  sterna biologicals Gmbh &Co KG1081
  Sucampo Pharmaceuticals, Inc.1091
  Sun Pharma Advanced Research Company Ltd.1101
  SWITCH Biotech LLC1111
  Takeda Pharmaceutical Company Limited1121
  Thesan Pharmaceuticals, Inc.1131
  Tioga Pharmaceuticals, Inc.1141
  Torrent Pharmaceuticals Limited1151
  Valeant Pharmaceuticals International, Inc.1161
  Vicore Pharma AB1171
  Vitae Pharmaceuticals, Inc.1181
  VivaCell Biotechnology Espana S.L.1191
  Xencor, Inc.1201
  Ziarco Pharma Ltd1211
Atopic Dermatitis Therapeutics Assessment12215
  Assessment by Monotherapy Products1221
  Assessment by Target1235
  Assessment by Mechanism of Action1285
  Assessment by Route of Administration1332
  Assessment by Molecule Type1352
Drug Profiles137215
  A-3914 Drug Profile1371
  A-5425 Drug Profile1381
  AKP-11 Drug Profile1392
  Allergen for House Dust Mite Induced Atopic Dermatitis Drug Profile1411
  ALX-101 Drug Profile1421
  AM-1030 Drug Profile1431
  AMG-0101 Drug Profile1442
  Anatabine Drug Profile1463
  ANB-020 Drug Profile1492
  apremilast Drug Profile15111
  Aptamers to Inhibit Galectin-3 for Atopic Dermatitis Drug Profile1621
  ARGX-112 Drug Profile1631
  ARN-077 Drug Profile1641
  asimadoline Drug Profile1652
  AVX-001 Drug Profile1671
  B-244 Drug Profile1681
  baricitinib Drug Profile1697
  BB-2702 Drug Profile1761
  BBI-2000 Drug Profile1771
  BBI-5000 Drug Profile1781
  bertilimumab Drug Profile1794
  betamethasone valerate Drug Profile1831
  Biologic for Atopic Dermatitis and Eczema Drug Profile1841
  brilacidin tetrahydrochloride Drug Profile1859
  BTX-1204 Drug Profile1941
  C-21 Drug Profile1952
  CBP-174 Drug Profile1971
  CBP-201 Drug Profile1981
  CCX-6239 Drug Profile1991
  CDE-001 Drug Profile2001
  Cis-Urocanic Acid Drug Profile2013
  cobamamide Drug Profile2041
  crisaborole Drug Profile2055
  CT-101 Drug Profile2101
  CT-103 Drug Profile2111
  CT-327 Drug Profile2123
  CT-340 Drug Profile2151
  cyclosporine Drug Profile2161
  dalazatide Drug Profile2175
  DMT-210 Drug Profile2221
  Drug for Atopic Dermatitis Drug Profile2231
  dupilumab Drug Profile2246
  FB-825 Drug Profile2301
  fevipiprant Drug Profile2312
  FIB-116 Drug Profile2331
  Furestem-AD Drug Profile2341
  GBR-830 Drug Profile2351
  GLPG-2534 Drug Profile2361
  GSK-3772847A Drug Profile2371
  Histimex Drug Profile2381
  HS-378 Drug Profile2391
  IDP-124 Drug Profile2401
  JTE-052 Drug Profile2411
  KPI-150 Drug Profile2421
  LCB-030110 Drug Profile2431
  lebrikizumab Drug Profile2443
  LEKTI-6 Drug Profile2471
  LEO-32731 Drug Profile2481
  LEO-39652 Drug Profile2491
  MEDI-9314 Drug Profile2501
  mepolizumab Drug Profile2515
  MLR-1130 Drug Profile2561
  mometasone furoate Drug Profile2571
  Monoclonal Antibody to Antagonize PAR-2 for Atopic Dermatitis and Inflammation Drug Profile2581
  Monoclonal Antibody to Inhibit IL-4 and IL-13 for Atopic Dermatitis Drug Profile2591
  Monoclonal Antibody to Target Th22 cell/IL-22 pathway for Inflammatory Bowel Diseases, Atopic Dermatitis and Colorectal Cancer Drug Profile2601
  N-oleoylethanolamine Drug Profile2611
  nemolizumab Drug Profile2621
  NPH-12 Drug Profile2631
  NS-141 Drug Profile2641
  OC-000459 Drug Profile2652
  OC-2417 Drug Profile2671
  octenidine hydrochloride Drug Profile2681
  OLX-103 Drug Profile2691
  omiganan pentahydrochloride Drug Profile2702
  OPA-15406 Drug Profile2722
  P-10 Drug Profile2741
  P-148 Drug Profile2751
  PAC-14028 Drug Profile2762
  Peptide to Antagonize CX3CR1 for Atopic Dermatitis Drug Profile2781
  Peptides to Antagonize TNFR-1 for Atopic Dermatitis Drug Profile2791
  PF-04965842 Drug Profile2801
  PH-10 Drug Profile2813
  PL-601 Drug Profile2841
  PMA-101R Drug Profile2851
  PMA-201 Drug Profile2861
  PMA-411R Drug Profile2871
  PR-022 Drug Profile2881
  prednisone Drug Profile2891
  PZ-235 Drug Profile2901
  Q-301 Drug Profile2911
  Qi-507 Drug Profile2921
  roflumilast Drug Profile2935
  RTU-1096 Drug Profile2982
  RVT-501 Drug Profile3001
  SB-011 Drug Profile3011
  SB-414 Drug Profile3021
  secukinumab Drug Profile30313
  SIG-1311 Drug Profile3161
  SIG-1322 Drug Profile3171
  Small Molecule for Atopic Dermatitis Drug Profile3181
  Small Molecule to Modulate S1PR1 for Atopic Dermatitis Drug Profile3191
  Small Molecules for Atopic Dermatitis Drug Profile3201
  Small Molecules for Atopic Dermatitis Drug Profile3211
  Small Molecules to Antagonize TNFR-1 for Atopic Dermatitis Drug Profile3221
  SP-14019 Drug Profile3231
  SUN-0597 Drug Profile3242
  SWT-01113 Drug Profile3261
  SWT-05141 Drug Profile3271
  Synthetic Peptides to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders Drug Profile3281
  tacrolimus Drug Profile3291
  tezepelumab Drug Profile3302
  tralokinumab Drug Profile3322
  upadacitinib tartrate Drug Profile3342
  ustekinumab Drug Profile3366
  VTP-38543 Drug Profile3421
  WBI-1001 Drug Profile3432
  WOL-071007 Drug Profile3451
  XmAb-7195 Drug Profile3461
  YJC-10592 Drug Profile3471
  Zafi-1 Drug Profile3481
  ZPL-389 Drug Profile3492
  ZPL-521 Drug Profile3511
Atopic Dermatitis Dormant Projects35210
Atopic Dermatitis Discontinued Products3622
Atopic Dermatitis Product Development Milestones36410
  Featured News &Press Releases3641
    Jul 13, 2016: Pfizer Announces the Publication of Final Results from Two Pivotal Phase 3 Studies of Crisaborole Topical Ointment in Patients with Mild to Moderate Atopic Dermatitis3641
    Jul 06, 2016: AnaptysBio Initiates Multiple Ascending Dose Cohorts In ANB020 Phase 1 Clinical Trial3641
    Jul 05, 2016: AnGes Announces Top-Line Results for Japanese PhaseIII Clinical Trial of NF-B Decoy Oligonucleotide for Atopic Dermatitis3651
    Jun 13, 2016: Ziarco reports positive Phase 2a study results with ZPL-389 in moderate to severe atopic dermatitis patients3651
    Jun 09, 2016: PuriCore successfully completes Pre-IND Meeting with the FDA on PR022 for Atopic Dermatitis3661
    Jun 06, 2016: Sanofi and Regeneron Announce that Dupilumab Used with Topical Corticosteroids was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients3671
    May 23, 2016: Medimetriks announces the results of a successful Phase 2 trial of MM36 in Atopic Dermatitis; Study results and design published in the Journal of the American Academy of Dermatology3681
    May 16, 2016: Ziarco Pharma Announces Positive Top Line Results from Phase 2a Study in Moderate to Severe Atopic Dermatitis with its Oral Lead Compound ZPL-3893691
    Apr 01, 2016: Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients3692
    Mar 22, 2016: Anacor Pharmaceuticals Announces FDA Acceptance of NDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitis3711
    Mar 10, 2016: AnaptysBio Announces First-In-Human Dosing of Anti-IL-33 Antibody3711
    Mar 05, 2016: Chugai Announces Phase II Global Study Results of Nemolizumab (CIM331) in Late-breaking Research Forums at AAD3721
    Feb 23, 2016: Anacor Pharmaceuticals Announces Late-Breaking Oral Presentation of Crisaborole Topical Ointment, 2% Phase III Pivotal Data at the 74th Annual Meeting of the American Academy of Dermatology3731
    Feb 08, 2016: KPI Therapeutics Initiates Research Program In Skin Diseases3731
    Jan 08, 2016: Anacor Pharmaceuticals to Present Data From Long-Term Safety Study of Crisaborole Topical Ointment, 2% in Patients With Mild-to-Moderate Atopic Dermatitis at Upcoming Medical Conference3731
Appendix3742
  Methodology3741
  Coverage3741
  Secondary Research3741
  Primary Research3741

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Atopic Dermatitis - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Atopic-Dermatitis-Pipeline-Review-H2-2016-2088-16349>
  
APA:
Global Markets Direct - Market Research. (2016). Atopic Dermatitis - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Atopic-Dermatitis-Pipeline-Review-H2-2016-2088-16349>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.